News - Posters
Check out the posts below to learn the latest updates on our progress
- April 17 2023In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR-T and NK-like (CAR-TaNK) cells capable of complete ablation of B cells in the blood, bone marrow, and tissue in NSG-SGM3 CD34+ humanized miceAACR 2023
- September 15 2022In vivo generation of tumor-metabolism-regulated HER2-specific CAR+ cells eradicate established HER2+ gastric carcinomas with the novel subcutaneous route of administration of CD3-directed lentivector-loaded lymphocytes.
- April 8 2022In vivo delivery of a novel CD3-targeted Lentiviral Vector generates CD19 CAR-T cells in two different humanized mouse models and results in complete B cell depletion
AACR 2022 - April 8 2022Generation of tertiary lymphoid structures and CD3pos CD8pos CD56pos NKG2Dpos CAR TaNK cells following subcutaneous injection of CD3-directed lentiviral vector-loaded PBMC
AACR 2022 - April 9 2021Subcutaneous injection of total nucleated cells rapidly isolated following four-hour peripheral whole blood exposure to CD3-directed CAR-T lentiviruses with a synthetic driver results in robust CAR-T proliferation and anti-tumor immunity
AACR Annual Meeting 2021 - November 9 2020Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression
SITC 35th Anniversary Annual Meeting & Pre-Conference (virtual) - October 19 2020Logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumors
AACR Tumor Immunology & Immunotherapy 2020 - April 3 2019Same Day Transduction and In Vivo Expansion of a Chimeric Antigen Receptor with a Synthetic Driver Construct for Adoptive Cellular Therapy
AACR 2019 - April 3 2019A High-Throughput Screening Strategy for the Identification of Novel Lymphoproliferative Elements
AACR 2019 - April 3 2019CAB-CAR-T: The Prioritization of Cell Surface Protein Targets for Conditionally Active Biologics to Treat All Solid Tumors
AACR 2019